Please assess the completion status of the following clinical trial:

Trial Title: Effect of a CCK-1R Agonist on Food Intake in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Both controls and patients will be female, 18 to 45 years old, and within 80-120% of ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will be evaluated using the following guidelines:~Normal Controls:~* No current or past psychiatric illness~* No history of binge eating or vomiting~* 80-120% ideal weight~* Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or surgically sterile)~* If of childbearing potential, willing to use an acceptable method of birth-control (please see list in Exclusion section)~Patients with Bulimia Nervosa:~* DSM-IV (diagnostic statistical manual - American Psychiatric Association) criteria for bulimia nervosa~* Duration of illness \> 1 year~* Purging after binges via self-induced vomiting~(Same as controls for remaining inclusion criteria)~Exclusion Criteria:~Normal Controls:~* Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium, chloride, CO2), glucose, BUN (blood urea nitrogen), creatinine, Alk Phos, ALT (SGPT), AST (SGOT), LDH, total bilirubin, total protein, albumin, globulin, A/G ratio, calcium, phosphorus, uric acid, cholesterol, triglyceride~* ALT outside of upper limit of normal: Chem-1~* History of gallstones, pancreatitis or cholecystitis~* Current medication~* Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006)~* Drug or alcohol abuse in last 3 mts~* Pregnancy~* Unable or unwilling to use highly effective methods of contraception for the duration of the study until an insignificant amount of the investigational product remains in the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective methods of contraception are:~  * Implants of levonorgestrel, or~ * Injectable progestogen, or~ * Oral birth control pills for at least 3 monthly cycles prior to administration of study drug + continuation for 24 hrs after last dose of study drug, or~ * Double-barrier method (e.g. condom, diaphragm) with spermicide~Note-Significant medical illness is any illness requiring continued care, i.e. chronic medication. Examples include hypertension, diabetes, and systemic lupus erythematosis. Subjects with seasonal allergies or occasional urinary tract infections will be included.~Patients with Bulimia Nervosa:~* Same as controls

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 'Instructions to eat normally' (Type: PLACEBO_COMPARATOR): 'Instructions to eat normally' Placebo 1 mg dose
- 2 'Instructions to eat normally' (Type: ACTIVE_COMPARATOR): 'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
- 3 'Instructions to eat normally' (Type: PLACEBO_COMPARATOR): 'Instructions to eat normally' 2 mg placebo
- 4 'Instructions to eat normally' (Type: ACTIVE_COMPARATOR): 'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
- 5 'Instructions to eat normally' (Type: PLACEBO_COMPARATOR): 'Instructions to eat normally' 4 mg placebo
- 6 'Instructions to eat normally' (Type: ACTIVE_COMPARATOR): 'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
- 7 Instructions to binge eat (Type: PLACEBO_COMPARATOR): Instructions to binge eat 4 mg placebo
- 8 Instructions to binge eat (Type: ACTIVE_COMPARATOR): Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'

Based on this trial design, predict the completion outcome and termination type (if applicable).